GlassScriptPhysician profile
Patricia Wilcox
NPI 1427039056
$4,748.15
in general payments reported to CMS, 2019-2025
36 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $194 · 2021: $882 · 2022: $472 · 2023: $391 · 2024: $767 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.13 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,217.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.78 | 2021-2025 | Jardiance |
| Abbvie INC. | $366.68 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $318.02 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $284.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $226.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $185.16 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $151.63 | 2019-2025 | Kisunla |
| Exact Sciences Corporation | $144.91 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $134.05 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $121.40 | 2019 | |
| Allergan, INC. | $110.08 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $104.31 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $95.55 | 2022 | |
| Astellas Pharma US INC | $71.03 | 2019-2025 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $69.21 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $66.03 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbott Laboratories | $49.14 | 2025 | Eterna |
| Tris Pharma INC | $45.87 | 2019-2025 | Dyanavel Xr |
| Hologic Sales and Service, LLC | $38.01 | 2025 | Aptima |
| Amarin Pharma, INC. | $33.56 | 2019 | |
| Organon LLC | $32.32 | 2025 | Nexplanon |
| Corium, LLC | $26.79 | 2024 | Azstarys |
| Novartis Pharmaceuticals Corporation | $26.39 | 2019 | |
| Mayne Pharma Commercial LLC | $21.25 | 2025 | |
| Galderma Laboratories, L.P. | $21.04 | 2025 | |
| Axsome Therapeutics, INC. | $18.68 | 2025 | Symbravo |
| Ironwood Pharmaceuticals, INC | $17.42 | 2019 | |
| Genentech USA, INC. | $16.22 | 2019 | |
| Celgene Corporation | $14.40 | 2019 | |
| Lundbeck LLC | $14.30 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $12.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.45 | 2019 | |
| Amgen INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.